Meyer Handelman Co. held its stake in shares of Celgene Corporation (NASDAQ:CELG) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,100 shares of the biopharmaceutical company’s stock at the end of the first quarter. Meyer Handelman Co.’s holdings in Celgene Corporation were worth $261,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Diversified Trust Co boosted its stake in shares of Celgene Corporation by 0.4% in the first quarter. Diversified Trust Co now owns 2,342 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 9 shares during the last quarter. Arete Wealth Advisors LLC boosted its stake in shares of Celgene Corporation by 0.3% in the third quarter. Arete Wealth Advisors LLC now owns 3,106 shares of the biopharmaceutical company’s stock worth $325,000 after buying an additional 10 shares during the last quarter. Hodges Capital Management Inc. boosted its stake in shares of Celgene Corporation by 0.8% in the fourth quarter. Hodges Capital Management Inc. now owns 2,152 shares of the biopharmaceutical company’s stock worth $249,000 after buying an additional 17 shares during the last quarter. First Heartland Consultants Inc. boosted its stake in shares of Celgene Corporation by 0.5% in the third quarter. First Heartland Consultants Inc. now owns 5,914 shares of the biopharmaceutical company’s stock worth $618,000 after buying an additional 30 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in shares of Celgene Corporation by 0.8% in the first quarter. Quadrant Capital Group LLC now owns 4,073 shares of the biopharmaceutical company’s stock worth $492,000 after buying an additional 34 shares during the last quarter. Hedge funds and other institutional investors own 78.26% of the company’s stock.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (NASDAQ CELG) opened at 134.31 on Friday. Celgene Corporation has a one year low of $94.42 and a one year high of $134.56. The company has a 50-day moving average of $119.20 and a 200 day moving average of $119.73. The company has a market cap of $104.87 billion, a P/E ratio of 50.44 and a beta of 1.82. Celgene Corporation also was the recipient of unusually large options trading activity on Wednesday. Traders purchased 1,270 put options on the stock. This is an increase of 232% compared to the typical daily volume of 382 put options.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.47 by $0.21. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The firm had revenue of $2.96 billion for the quarter, compared to analyst estimates of $3.04 billion. During the same period in the prior year, the firm posted $1.32 earnings per share. The company’s quarterly revenue was up 17.8% compared to the same quarter last year. Equities research analysts predict that Celgene Corporation will post $7.29 EPS for the current year.

WARNING: “Celgene Corporation (CELG) Stake Maintained by Meyer Handelman Co.” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/06/24/meyer-handelman-co-holds-position-in-celgene-co-celg-updated.html.

A number of brokerages recently weighed in on CELG. Oppenheimer Holdings, Inc. set a $148.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, February 25th. Canaccord Genuity set a $156.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Saturday, February 25th. Jefferies Group LLC set a $154.00 price objective on shares of Celgene Corporation and gave the stock a “buy” rating in a research note on Saturday, May 13th. BTIG Research reaffirmed a “buy” rating and issued a $138.00 price objective on shares of Celgene Corporation in a research note on Monday, May 1st. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $162.00 price objective on shares of Celgene Corporation in a research note on Monday, May 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $139.49.

In other Celgene Corporation news, Director Gilla Kaplan sold 14,033 shares of the company’s stock in a transaction on Thursday, March 30th. The shares were sold at an average price of $123.83, for a total transaction of $1,737,706.39. Following the sale, the director now directly owns 73,109 shares of the company’s stock, valued at $9,053,087.47. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Insiders have sold 232,538 shares of company stock worth $30,781,803 over the last ninety days. Insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.